Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma
Shanghai Junshi Biosciences, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the pre-specified interim analysis of the RENOTORCH study (NCT04394975) has been completed. RENOTORCH is a multi-center, randomized, open-label, active-controlled phase 3 clinical study evaluating toripalimab in combination with axitinib for the first-line treatment of patients with intermediate to high risk, unresectable or distant metastatic renal cell carcinoma (“RCC”). The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint of progression-free survival (“PFS”, based on independent radiographic review) has met the pre-defined efficacy boundary. Junshi Biosciences will communicate with regulatory authorities regarding matters related to the supplemental new drug application in the near future.
Globally, renal carcinoma is the third most common type of malignancy in the urinary system, and RCC accounts for 80%-90% of all cases. According to data published in the Chinese Medical Journal, in 2022, there were approximately 77,000 new cases of renal carcinoma and 46,000 deaths due to this disease in China. About one-third of the renal cell carcinoma patients had distant metastasis at initial diagnosis, while 20%-50% of the patients with localized tumors developed distant metastasis after nephrectomy. According to the risk classification of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), the median overall survival (“OS”) of patients with low, medium and high risk metastatic RCC receiving anti-vascular targeted treatment was 35.3, 16.6 and 5.4 months, respectively. Therefore, the need for new treatment options is more urgent for patients with medium and high risk advanced RCC compared to low-risk patients.
In recent years, PD-(L)1 inhibitors combined with anti-vascular targeted drugs have achieved success in the first-line treatment of advanced RCC in many countries around the world, replacing anti-vascular targeted drug monotherapy as the new standard. Compared to anti-vascular targeted drug monotherapy, the combination of PD-(L)1 monoclonal antibody and anti-vascular targeted drugs has demonstrated significant improvements in patients’ PFS, objective response rate (“ORR”), and OS. However, no therapy combining PD-(L)1 therapy with anti-vascular targeted drugs for the first-line treatment of advanced RCC has been approved in China.
As the first pivotal phase 3 study of immunotherapy for patients with advanced RCC in China, RENOTORCH is a multi-center, randomized, open-label, active-controlled study aiming to evaluate the efficacy and safety of toripalimab in combination with axitinib versus sunitinib monotherapy for the first-line treatment of patients with intermediate to high-risk unresectable or metastatic RCC. Based on the interim analysis of the study, toripalimab in combination with axitinib for the first-line treatment of patients with advanced RCC significantly reduced the risk of disease progression or death compared to sunitinib monotherapy, while improving secondary endpoints such as ORR. The safety profile of toripalimab in the study was consistent with known risks, and no new safety signals were identified. Further details on the study data will be presented at an upcoming international academic conference.
“Thanks to the collective efforts of the investigators, patients, R&D teams and many others, the RENOTORCH study has been a great success,” said Dr Jianjun ZOU, Global Research and Development President of Junshi Biosciences. “This study represents a crucial milestone for our company as an innovative Chinese pharmaceutical company that aims to address the nation’s unmet medical needs. We believe that RENOTORCH’s positive results will help bridge the gap in renal cancer PD-(L)1 immunotherapy in China, and we will take all the necessary steps to commercialize this achievement and provide new and effective combination immunotherapy options for domestic patients.”
- Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
- Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
- Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
- Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
- Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more